Non-invasive Left-sided Cervical Vagus Nerve Stimulation for Atrioventricular Reentrant Tachycardia

Atrioventricular Reentrant Tachycardia Clinical Trial

Official title:

Non-invasive Left-sided Cervical Vagus Nerve Stimulation for Atrioventricular Reentrant Tachycardia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06219343
• Other study ID #: ES-2023-175-03
• Status: Recruiting
• Phase: N/A
• Start date: January 10, 2023
• Est. completion date: December 30, 2024

Study information

• Verified date: January 2024
• Source: Guangzhou Medical University
• Contact: Ai-lan Chen
• Phone: 13719198832
• Email: 1228327958[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this Interventional clinical trials in atrioventricular reentrant tachycardia patients. The main question it aims to answer whether non-invasive vagus nerve stimulation could be effective in restoring rhythm. Patients will receive non-invasive vagus nerve electrical stimulation under catheter evoked and cardiac monitoring to observe their heart rhythm changes.

Description:

Participants will be treated with non-invasive electrical stimulation of the left vagus nerve in the neck. After routine induction of atrioventricular reentrant tachycardia prior to radiofrequency ablation, the electrode patch was placed on the patient's left cervical vagal body surface localization, i.e., between the sternocleidomastoid muscle and the trachea where the left common carotid artery pulsation could be palpated, and resuscitation was performed using non-invasive electrical stimulation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 30, 2024
• Est. primary completion date: December 10, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. The relevant diagnostic criteria in the Guidelines for the Diagnosis and Treatment of Supraventricular Tachycardia (svt) need to be met.

2. All need to be free of psychiatric abnormalities, verbal communication disorders, and have good compliance.

3. The patients and their families gave informed consent and signed the informed consent form.

Exclusion Criteria:

1. Does not meet the relevant diagnostic criteria in the Guidelines for the Diagnosis and Treatment of Supraventricular Tachycardia (svt).

2. Mental anomalies, verbal communication disorders, poor adherence

3. Those who do not consent to participate in this clinical trial

Related Conditions & MeSH terms

• Atrioventricular Reentrant Tachycardia
• Tachycardia
• Tachycardia, Atrioventricular Nodal Reentry
• Tachycardia, Supraventricular

Intervention

Device:
• Non-invasive vagus nerve stimulation
Patient undergoes non-invasive vagus nerve stimulation during tachycardia episodes to see if reentry is possible

Locations

Country	Name	City	State
China	Ai-lan Chen	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Jingye Tai

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Whether the tachycardia is repetitive or not	Determining whether a tachycardia is reentrant on the basis of the ambulatory electrocardiogram	10minutes
Secondary	Parameters leading to tachycardia resumption	Intensity of electrical stimuli leading to tachycardia resumption	10minutes